{"id":2292,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2015-04-29","marketCap":1848.54,"name":"Viking Therapeutics Inc","phone":"18587044660.0","outstanding":100.03,"symbol":"VKTX","website":"https://vikingtherapeutics.com/","industry":"Biotechnology"},"price":19.0825,"year":2023,"month":12,"day":16,"weekday":"Saturday","title":"Historical Stock Splits and Corporate Actions of Viking Therapeutics Inc","date":"2023-12-16","url":"/posts/2023/12/16/VKTX","content":[{"section":"2015 - Viking Therapeutics Inc goes public","text":"Viking Therapeutics Inc, a clinical-stage biopharmaceutical company, goes public on the NASDAQ stock exchange under the ticker symbol VKTX."},{"section":"March 29, 2017 - Viking Therapeutics announces 1-for-10 reverse stock split","text":"Viking Therapeutics announces a reverse stock split, consolidating 10 shares into 1 share to maintain compliance with NASDAQ minimum bid price requirements."},{"section":"August 28, 2017 - Viking Therapeutics announces 1-for-30 reverse stock split","text":"Viking Therapeutics announces another reverse stock split, consolidating 30 shares into 1 share to maintain compliance with NASDAQ minimum bid price requirements."},{"section":"April 18, 2018 - Viking Therapeutics announces 1-for-10 reverse stock split","text":"Viking Therapeutics announces yet another reverse stock split, consolidating 10 shares into 1 share to maintain compliance with NASDAQ minimum bid price requirements."},{"section":"June 15, 2020 - Viking Therapeutics announces pricing of public offering","text":"Viking Therapeutics announces the pricing of an underwritten public offering, issuing 11,500,000 shares of common stock at a price of $6.50 per share."},{"section":"June 18, 2020 - Viking Therapeutics completes public offering","text":"Viking Therapeutics completes the previously announced underwritten public offering, resulting in the issuance of 11,500,000 shares of common stock."},{"section":"September 3, 2021 - Viking Therapeutics announces 1-for-10 reverse stock split","text":"Viking Therapeutics announces yet another reverse stock split, consolidating 10 shares into 1 share to maintain compliance with NASDAQ minimum bid price requirements."},{"section":"Summary","text":"Viking Therapeutics Inc has undergone multiple reverse stock splits to meet NASDAQ compliance requirements. Additionally, the company has conducted successful public offerings to raise capital and fund its operations."}],"tags":["CrossOver55","Long","Biotechnology"],"news":[{"category":"company","date":1702388700,"headline":"Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?","id":124476717,"image":"https://g.foolcdn.com/editorial/images/757942/growth-stock.jpg","symbol":"VKTX","publisher":"Yahoo","summary":"Both of these pharma stocks could be big winners. But one stock screens as a better buy from a risk standpoint.","url":"https://www.fool.com/investing/2023/12/12/better-growth-stock-viking-therapeutics-or-iovance/?source=eptyholnk0000202\u0026amp;utm_source=yahoo-host\u0026amp;utm_medium=feed\u0026amp;utm_campaign=article\u0026amp;.tsrc=rss"},{"category":"company","date":1702041260,"headline":"Why Viking Therapeutics Was Crushing It This Week","id":124386144,"image":"https://s.yimg.com/ny/api/res/1.2/tmlP5dMQzN9ooOJ3frgspw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD01ODY-/https://media.zenfs.com/en/motleyfool.com/bf8c02466428727b90aee47d90a58db4","symbol":"VKTX","publisher":"Yahoo","summary":"A multibillion-dollar deal in the healthcare industry helped lift the stock of a company, Viking Therapeutics (NASDAQ: VKTX), not directly involved in the transaction.  As a result, according to data compiled by S\u0026P Global Market Intelligence, Viking's share price was up by a whopping 39% week to date as of Friday before market open.  The week kicked off with global pharmaceutical company Roche (OTC: RHHBY) announcing it signed an agreement essentially to acquire clinical-stage biotech Carmot Therapeutics.","url":"https://finance.yahoo.com/m/37d6ee32-db00-326d-806c-bddad8093a93/why-viking-therapeutics-was.html"},{"category":"company","date":1702037100,"headline":"Viking Therapeutics call volume above normal and directionally bullish","id":124412662,"image":"","symbol":"VKTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3248102185"},{"category":"company","date":1701944100,"headline":"Biotech Alert: Searches spiking for these stocks today","id":124364683,"image":"","symbol":"VKTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3246085759"},{"category":"company","date":1701785407,"headline":"Viking: Results From 2 Clinical Trials Of Weight Loss Drug Ahead, Other Catalysts On Tap","id":124310220,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1468999087/image_1468999087.jpg?io=getty-c-w1536","symbol":"VKTX","publisher":"SeekingAlpha","summary":"Viking has four catalysts on tap in H1'24 and has cash for years to come. Read why my analysis of VKTX stock suggests a buy rating.","url":"https://seekingalpha.com/article/4656106-viking-results-from-two-clinical-trials-of-weight-loss-drug-ahead-other-catalysts-on-tap"},{"category":"company","date":1701687540,"headline":"Viking Therapeutics rises on Roche acquiring peer Carmot","id":124279780,"image":"","symbol":"VKTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3240667732"},{"category":"company","date":1701685500,"headline":"Weight-loss drug developers rise after Roche agrees to buy Carmot","id":124279739,"image":"","symbol":"VKTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3240625716"},{"category":"company","date":1701675300,"headline":"RIOT, VKTX and FREY are among pre market gainers","id":124282773,"image":"","symbol":"VKTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3240426805"},{"category":"company","date":1701672060,"headline":"Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), BioNTech SE (BNTX) and Viking Therapeutics (VKTX)","id":124316147,"image":"","symbol":"VKTX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3241328675"},{"category":"company","date":1701662820,"headline":"Viking Therapeutics Breaks Above 200-Day Moving Average - Bullish for VKTX","id":124316149,"image":"","symbol":"VKTX","publisher":"Market News Video","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3241091377"},{"category":"company","date":1701656520,"headline":"Noteworthy Monday Option Activity: VKTX, SGEN, SAIA","id":124286983,"image":"","symbol":"VKTX","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3240940022"},{"category":"company","date":1701638040,"headline":"Obesity Drugs Have Multi-Billion-Dollar Market Potential, Says Oppenheimer — Here Are 2 Stocks to Take Advantage","id":124274748,"image":"https://media.zenfs.com/en/tipranks_452/7e4aaba050fc340c90cab664d915f228","symbol":"VKTX","publisher":"Yahoo","summary":"A key to success in the stock market is a touch of foresight. Not quite precognition, but an ability to spot and put together clues and trends, to discern the ‘next big thing’ before it hits. This is true in every stock sector, but today we’ll focus on biotech. The biotech firms have famously high product lead times, paired with equally high overhead expenses; it’s a combination that would make them unlikely investments, except that when a drug is approved, it can turn into a blockbuster. Succes","url":"https://finance.yahoo.com/news/obesity-drugs-multi-billion-dollar-211400382.html"}]}